The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I […]
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
The fact that a person for the first time has received a heart transplant from a pig and it was a genetically modified pig made big news this week. Organ transplant waiting lists are a huge problem so if this kind of approach can be proven to be safe and effective, it would be a
Recommended reads: pig heart transplant, lasers, $11K pub fee Read More »
If you celebrate the Thanksgiving holiday I hope you had a nice one and, right before it started a new article popped on the scene about the CRISPR babies. Before we discuss those three gene-edited people, who are now growing up into little kids, we hit a milestone on our YouTube Stem Cell Channel with
Regenerative reads: 3 CRISPR babies, FDA warning, diabetes, pubs Read More »
This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant
Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »
Sometimes things in the stem cell world get complicated and this week is no exception with news of Orchard Therapeutics dropping a seemingly life-saving clinical trial. There are hundreds of kids who could possibly benefit. Rotten apple decision from Orchard Therapeutics From David Jensen at California Stem Cell Report we have something of a scoop:
Weekly reads: Orchard punts on life-saving SCID trial, cardioids with cavities, more Read More »
One of my main research interests is in oncodevelopmental factors. These include factors that are important both for normal stem cell biology and development as well as driving cancer when misregulated. One example includes the MYC family of proto-oncogenes. When I was a postdoc I got especially interested in trying to understand the normal role
Weekly reads: oncodevelopmental factors, iPSC cancer vaccine, more Read More »
There are many ways to classify different stem cells. These differences include yours versus someone else’s cells. Another distinct in a clinical sense is what we call an autologous vs allogeneic stem cell transplant. This post is focused on the difference between allogeneic (someone else’s cells) and autologous (your own) stem cell injections. As a
Autologous vs allogeneic: all you need to know on therapy Read More »
Sometimes change takes a very long time, but with brain organoids or advocating for better information for patients at Clinicaltrials.gov, after waiting you can see some interesting developments. These are two of the regenerative medicine stories of the week, along with some striking research papers. Clinicaltrials.gov Some of us have been advocating for improvements at
Regenerative reads: brain organoids, Clinicaltrials.gov change Read More »
Organoids and especially brain organoids, which are made from pluripotent stem cells, are one of the most interesting developmental biology technologies of the last half a dozen or so years. Still some folks can’t help but get carried away when thinking about brain organoids it seems. A new Science paper from a team led by
Dissecting that Neanderthal brain organoids Science pub Read More »